Data as of Mar 14
| +0.46 / +0.59%|
The 24 analysts offering 12-month price forecasts for Vertex Pharmaceuticals Inc have a median target of 94.00, with a high estimate of 115.00 and a low estimate of 68.00. The median estimate represents a +20.02% increase from the last price of 78.32.
The current consensus among 28 polled investment analysts is to Buy stock in Vertex Pharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.